Long-term follow up of patients with WHO grade 2 oligodendroglioma.
Louise CarstamFrancesco LatiniOle SolheimJiri BartekLars K PedersenMaria ZetterlingStanislav BeniaminovKristin SjåvikMats RyttleforsMargret JensdottirBertil RydenhagAnja SmitsAsgeir S JakolaPublished in: Journal of neuro-oncology (2023)
Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival.